Session

Special session of the Prostate Cancer Prevention Group

Special session

  • Location:
    Room Stockholm, North Hall (Level 1)
  • Chairs:
     J. Cuzick, London (GB)
     A. Stenzl, Tübingen (DE)
     M. Wirth, Dresden (DE)
  • Aims and objectives of this session

    Focus on how best to identify individuals for active surveillance and what the follow up protocols should be

Welcome and introduction
 
 J. Cuzick, London (GB)
 
 A. Stenzl, Tübingen (DE)
 
 M. Wirth, Dresden (DE)
Early detection
 
Moderator:
 J. Cuzick, London (GB)
ProtecT
 F.C. Hamdy, Oxford (GB)
ERSPC
 J. Hugosson, Göteborg (SE)
PLCO
 H. Parnes, Bethesda (US)
Question and answers
Risk factors and biomarkers for screening and triage
 
Moderator:
 A. Stenzl, Tübingen (DE)
Familial and genetic factors: New SNPs and panels
 R.A. Eeles, London (GB)
Dietary and lifestyle factors
 T. Key, Oxford (GB)
The role of miRNA in oncogenesis and progression
 M. Wirth, Dresden (DE)
Questions and answers (risk factors)
Blood and urine-based biomarkers
 J.A. Schalken, Nijmegen (NL)
Tissue-based biomarkers: CCP
 J. Cuzick, London (GB)
Imaging-based biomarkers: mpMRI
 P. Albers, Düsseldorf (DE)
Questions and answers (Biomarkers)
Break
Management of low-risk cancer and preventive therapy
 
Moderator:
 M. Wirth, Dresden (DE)
Observation or active surveillance or curative treatment: What do PIVOT data tell us?
 T.J. Wilt, Minneapolis (US)
Observation or active surveillance or curative treatment: What do SPCG-4 data tell us?
 A. Bill-Axelson, Uppsala (SE)
Prospective validation of active surveillance: PRIAS
 C.H. Bangma, Rotterdam (NL)
Questions and answers (Management of low risk cancer)
5-α Reductase inhibitors: Do they prevent only low-grade disease and increase high-grade disease?
 C.G. Roehrborn, Dallas (US)
Aspirin
 M. Thorat, London (GB)
Nutraceuticals
 V. Fradet, Quebec (CA)
Questions and answers (Preventive therapy)
Consensus panel discussion
 
Moderator:
 J. Cuzick, London (GB)